Breda, the Netherlands/Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment ...
ARGX-113 treatment resulted in a strong clinical improvement over placebo during the entire duration of the study 75% of ARGX-113 treated patients had a clinically meaningful and statistically ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results